Login

Journal Front Page

News & Events

  • April 2024 Issue delayed
    • Dear Researcher, It Pleased to inform you that, Asian Journal of Pharmaceutical Education and Research, Volume 13, Issue 2 (April 2024) Issue) schedule published on 15 April 2024 is delay due to some technical problem. It will published on 22 April 2024. Sorry for inconvenience. For other details You can vist the website http://www.ajper.com
  • Call for article for April 2024 issue
    • Submissions of Review, Research Article, Short Communication and Case study are being accepted for the current and future issues before 15 March, 2024 of this journal by online process or editor@ajper.com, or ajper.editor@gmail.com. Further information can be found at www.ajper.com.
  • January 2024 Issue published
    • Dear Researcher, It Pleased to inform you that, Asian Journal of Pharmaceutical Education and Research, has successfully launch Volume 13, Issue 1 (January 2024) Issue). You can find the article on http://ajper.com/current_issue.php Article also invited for the Next coming Issue from your side. For More details Visit: www.ajper.com
  • Application For Reviewer
    • We are now going to reconstitute our editorial board members of Reviewer. Please send your resume at ajper.editor@gmail.com and be a part of the editorial board member as Reviewer.
  • AJPER Impact facor
    • It is to pleasure that Ajper SJIF imact facor has increse from 5.019 to 7.014. Also global impact factor incresed from 0.654 to 0.765.
  • ICV
    • AJPER Rank with Index Copernicus Value 61.10 due to high reputation at International Level

Abstract

FORMULATION, DEVELOPMENT AND EVALUATION OF EMULGEL OF MOMETASONE FUROATE FOR EFFECTIVE TREATMENT OF TOPICAL DISEASE

Nimisha Singh*, Dr. Shailendra Bindaiya, Dr. S.K Lariya

Radharaman College of Pharmacy, Bhopal

ABSTRACT

Topical glucocorticoid formulations are widely used for effective treatment and control of a variety of dermatoses. Mometasone furoate is a medium potency, synthetic, non-fluorinated topical corticosteroid, indicated for the relief of inflammatory and pruritic manifestations of corticosteroid responsive dermatoses including psoriasis. The percutaneous absorption increases risk associated with systemic absorption of topically applied formulation. Controlled release of the drug to the skin could reduce the side effects while reducing percutaneous absorption. Emulgel have emerged as one of the most interesting topical delivery system as it has dual control release system i.e. gel and emulsion. One side the topical applications of the drug offers the potential advantages of delivering the drug directly to the site of action and secondly delivering the drug for extended period of time at the effected site. The aim of the present study was to develop an emulgel formulation of mometasone furoate using carbopol 941 as a gelling agent. In addition, light liquid paraffin as oil, Tween-20 and Span-20 as emulsifiers and propylene glycol as co-surfactant were selected for preparation of emulgel. The prepared emulgel were also evaluated for their physical properties, pH, drug content and rheological properties. Stability studies revealed no significant differences in formulation. Mometasone furoate emulgel formulation (F5) prepared by using carbapol 941 as gelling agent, emulsifying agent in its high level and liquid paraffin in its low level was the choice of formula, since it showed the highest drug release. So it can be concluded that topical emulgel enhanced permeation of mometasone furoate with avoidance of GIT adverse effect.

Keywords: Mometasone furoate, Emulgel, Psoriasis, In-vitro release test, Carbopol 941.


[Full Text Article]